Drugs / GR270774
last change Dec 2006 re-read 3 minutes ago

GR270774

Developed for
bacterial infectious disease with sepsis · gram-negative bacterial infections
Investigated by
GlaxoSmithKline · Hospital Authority, Hong Kong

Trials 1

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT00563134 Oct 2005 → Dec 2006 bacterial infectious disease with sepsis, gram-negative bacterial infections Hospital Authority, Hong Kong Suspended No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GR270774 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00563134 ↗
Route Intravenous “Three Days Continuous Intravenous Infusion” NCT00563134 ↗